EA201171371A1 - Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями - Google Patents
Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниямиInfo
- Publication number
- EA201171371A1 EA201171371A1 EA201171371A EA201171371A EA201171371A1 EA 201171371 A1 EA201171371 A1 EA 201171371A1 EA 201171371 A EA201171371 A EA 201171371A EA 201171371 A EA201171371 A EA 201171371A EA 201171371 A1 EA201171371 A1 EA 201171371A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- cardiovascular
- metabolic
- diseases
- polynesative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/367—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
- C07C69/68—Lactic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к липидным соединениям общей формулы (I) R-O-C(R)(R)-X (I), где Rпредставляет собой С-Салкильную группу, С-Салкенильную группу, содержащую 1-6 двойных связей или С-Салкинильную группу, содержащую 1-6 тройных связей; Rи Rодинаковы или отличаются друг от друга и их можно выбрать из различных заместителей; и Х представляет собой карбоновую кислоту или ее производные, такие как эфир карбоновой кислоты, ангидрид карбоновой кислоты, фосфолипид, или триглицерид, или карбоксамид; или к их фармацевтически приемлемым солям, сольватам, сольватам таких солей или к их пролекарствам. Настоящее изобретение относится также к фармацевтическим композициям и липидным композициям, включающим по меньшей мере одно соединение настоящего изобретения, и к таким соединениям для использования в качестве лекарственных препаратов или для использования при лечении, в частности при лечении заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17650309P | 2009-05-08 | 2009-05-08 | |
PCT/IB2010/001251 WO2010128401A1 (en) | 2009-05-08 | 2010-05-07 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201171371A1 true EA201171371A1 (ru) | 2012-05-30 |
EA021177B1 EA021177B1 (ru) | 2015-04-30 |
Family
ID=43050039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201171371A EA021177B1 (ru) | 2009-05-08 | 2010-05-07 | Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями |
Country Status (29)
Country | Link |
---|---|
US (2) | US8735436B2 (ru) |
EP (1) | EP2427415B1 (ru) |
JP (2) | JP5843755B2 (ru) |
KR (1) | KR101783817B1 (ru) |
CN (1) | CN102459142B (ru) |
AR (2) | AR078507A1 (ru) |
AU (1) | AU2010244136B2 (ru) |
BR (1) | BRPI1015120B8 (ru) |
CA (1) | CA2760877C (ru) |
CL (1) | CL2011002745A1 (ru) |
CO (1) | CO6430454A2 (ru) |
DK (1) | DK2427415T3 (ru) |
EA (1) | EA021177B1 (ru) |
ES (1) | ES2726765T3 (ru) |
HR (1) | HRP20190732T1 (ru) |
IL (1) | IL216171A (ru) |
MA (1) | MA33341B1 (ru) |
MX (2) | MX2011011614A (ru) |
MY (1) | MY165292A (ru) |
NZ (2) | NZ596386A (ru) |
PH (1) | PH12015500930A1 (ru) |
PL (1) | PL2427415T3 (ru) |
PT (1) | PT2427415T (ru) |
SG (1) | SG175401A1 (ru) |
TR (1) | TR201905768T4 (ru) |
TW (1) | TWI558395B (ru) |
UA (1) | UA109528C2 (ru) |
WO (1) | WO2010128401A1 (ru) |
ZA (2) | ZA201108163B (ru) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8741966B2 (en) | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
CA3083198A1 (en) | 2008-03-26 | 2009-10-01 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
TWI558395B (zh) * | 2009-05-08 | 2016-11-21 | 普諾華生物製藥諾治股份有限公司 | 新穎的脂質化合物 |
JP5735521B2 (ja) | 2009-10-30 | 2015-06-17 | タロス・リミテッドTharos Ltd. | リン脂質および中性脂質が強化されたオキアミ油を得る無溶媒の方法 |
GB201014633D0 (en) * | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
EA028535B1 (ru) | 2010-11-05 | 2017-11-30 | Пронова Биофарма Норге Ас | Способы лечения с применением липидных соединений |
WO2014083528A2 (en) * | 2012-12-02 | 2014-06-05 | Mahesh Kandula | Compositions and methods for the treatment of cardiovascular diseases and lipid disorders |
WO2014106846A2 (en) | 2013-01-03 | 2014-07-10 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
EP3578170A1 (en) * | 2013-02-28 | 2019-12-11 | Basf As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
PT2961727T (pt) * | 2013-02-28 | 2017-03-08 | Pronova Biopharma Norge As | Método de preparação do ácido 2-((5z,8z,11z,14z,17z)-icosa 5,8,11,14,17-pentaeniloxi)butanóico |
GB201409363D0 (en) | 2014-05-27 | 2014-07-09 | Avexxin As | Skin cancer treatment |
JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポc3を低下させるためのチアオキソ化合物の使用 |
JP2018510206A (ja) * | 2015-04-01 | 2018-04-12 | プロノヴァ バイオファーマ ノルゲ エーエス | アポc3を低下させるためのチアオキソ化合物の使用 |
KR102644400B1 (ko) * | 2015-04-28 | 2024-03-06 | 바스프 에이에스 | 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도 |
GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
GB201604316D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
EP3515422A1 (en) | 2016-09-21 | 2019-07-31 | Avexxin AS | Pharmaceutical composition |
WO2019083816A1 (en) | 2017-10-23 | 2019-05-02 | Epitracker, Inc. | FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME |
CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
CA3099561A1 (en) * | 2018-05-16 | 2019-11-21 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to aging |
WO2019224602A2 (en) | 2018-05-23 | 2019-11-28 | Northsea Therapeutics B.V. | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease |
MA53188A1 (fr) * | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
CA3148780A1 (en) | 2019-07-29 | 2021-02-04 | Bent PFAFFENROT | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN114981267A (zh) | 2020-01-15 | 2022-08-30 | 海帕瑞吉尼克斯股份有限公司 | 用于治疗肝脏疾病的mkk4抑制剂3-苯甲酰基-1h-吡咯并[2,3-b]吡啶衍生物 |
MX2023007347A (es) | 2020-12-22 | 2023-08-16 | Northsea Therapeutics B V | Terapias de combinacion que comprenden acidos grasos estructuralmente mejorados que contienen oxigeno para el tratamiento de la esteatohepatitis no alcoholica. |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909554A (en) | 1956-07-23 | 1959-10-20 | Monsanto Chemicals | Process for the manufacture of (alkylmercapto) alkyl sulfates |
GB1038723A (ru) | 1962-03-26 | |||
US4040781A (en) | 1974-06-06 | 1977-08-09 | Lever Brothers Company | Novel 2-(alkylsulfinyl)ethyl sulfates and compositions employing same |
US4032564A (en) * | 1974-09-09 | 1977-06-28 | Zoecon Corporation | Esters of cyclopropylalkanols |
GB1523276A (en) | 1974-09-20 | 1978-08-31 | Lafon Labor | Sulphur-containing amino compounds |
US4009211A (en) | 1975-07-29 | 1977-02-22 | Gulf Research & Development Company | Beta,beta-dialkylethylmercaptoethoxylate as new compounds |
US4209410A (en) | 1976-04-28 | 1980-06-24 | Phillips Petroleum Company | Lubricants |
EP0002007B1 (de) | 1977-11-11 | 1982-07-28 | Ciba-Geigy Ag | Neue Pyridindicarbonsäureesterderivate und ihre Gemische mit metallhaltigen Stabilisatoren sowie ihre Verwendung zur Stabilisierung von chlorhaltigen Thermoplasten |
JPS5570841A (en) | 1978-11-24 | 1980-05-28 | Konishiroku Photo Ind Co Ltd | Forming method of dye image |
US4368190A (en) | 1980-04-17 | 1983-01-11 | Merck & Co., Inc. | Immunologically active dipeptidyl 4-O-,6-O-acyl-2-amino-2-deoxy-D-glucose derivatives and methods for their preparation |
EP0050327B1 (de) | 1980-10-21 | 1984-06-20 | Roche Diagnostics GmbH | Neue schwefelhaltige Phospholipide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4411808A (en) | 1982-08-04 | 1983-10-25 | Exxon Research & Engineering Co. | Multifunctional additive for power transmission shift fluids |
US4775223A (en) | 1984-09-20 | 1988-10-04 | Canon Kabushiki Kaisha | Lactic acid derivative, liquid crystal composition containing same and liquid crystal device |
JPS6176438A (ja) * | 1984-09-20 | 1986-04-18 | Canon Inc | 乳酸誘導体 |
CA2010000A1 (en) | 1989-04-07 | 1990-10-07 | Paul B. Merkel | Photographic recording material containing a cyan dye-forming coupler |
JPH0451149A (ja) | 1990-06-19 | 1992-02-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
FR2663928B1 (fr) | 1990-06-27 | 1994-04-08 | Norsolor | Nouveaux composes acryliques soufres, un procede pour leur preparation et leur application a la synthese de nouveaux polymeres. |
EP0487809A1 (en) | 1990-11-28 | 1992-06-03 | Monsanto Europe S.A./N.V. | Rubber compositions having improved processability and improved rubber-vulcanisate properties |
JPH0543529A (ja) | 1991-08-10 | 1993-02-23 | Taisho Pharmaceut Co Ltd | アルカンアミドアンモニウム化合物 |
JP2793458B2 (ja) | 1992-03-19 | 1998-09-03 | 三井化学株式会社 | コネクター用ポリアミド系樹脂組成物およびコネクター |
JP2755279B2 (ja) | 1992-03-19 | 1998-05-20 | 三井化学株式会社 | 熱可塑性樹脂組成物およびその成形体 |
DE69431596D1 (de) | 1993-06-10 | 2002-11-28 | Wake Forest University Winston | (phospho)lipide zum bekämpfen einer hepatitis b-infektion |
JP3110918B2 (ja) | 1993-06-18 | 2000-11-20 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
DK70295A (da) | 1994-07-01 | 1996-01-02 | Ciba Geigy Ag | Titan- og zirkonium-komplekser af carboxylsyrer som korrosionsinhibitorer |
WO1996011908A1 (en) * | 1994-10-13 | 1996-04-25 | Peptide Technology Limited | Modified polyunsaturated fatty acids |
US7517858B1 (en) | 1995-06-07 | 2009-04-14 | The Regents Of The University Of California | Prodrugs of pharmaceuticals with improved bioavailability |
FR2741619B1 (fr) | 1995-11-28 | 1998-02-13 | Pf Medicament | Nouveaux derives de 2,3,5-trimethyl-4-hydroxy-anilides, leur preparation et leur application en therapeutique |
GB2328155B (en) * | 1996-04-12 | 2000-08-02 | Peptide Technology Pty Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
JP2001509165A (ja) * | 1997-01-24 | 2001-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | バリヤ機能の回復、表皮の分化の促進及び増殖の抑制のためのFXR、PPARα及びLXRαの活性剤の使用 |
US6060515A (en) | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
AU4806497A (en) * | 1997-10-01 | 1999-04-23 | Procter & Gamble Company, The | Glyoxylic compound comprising one or more active ingredient |
JPH11180929A (ja) | 1997-12-19 | 1999-07-06 | Asahi Glass Co Ltd | エステル誘導体 |
AU7240398A (en) | 1998-05-08 | 1999-11-29 | Rolf Berge | Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions |
FR2786187B1 (fr) | 1998-11-19 | 2001-11-09 | Univ Paris Curie | Composes du type 2-acylamino-2-deoxy-glucono-1,5-lactone, procede d'obtention, compositions les comportant et utilisations |
FR2792312B1 (fr) | 1999-04-15 | 2001-06-08 | Oreal | Composes (poly)thia-alcynoiques et leurs derives, compositions les comprenant et leur utilisation |
CA2375822A1 (en) | 1999-06-01 | 2000-12-07 | The University Of Texas Southwestern Medical Center | Substituted biaryl ether compounds |
US6723717B1 (en) | 1999-06-01 | 2004-04-20 | The University Of Texas Southwestern Medical Center | Sulfur-containing thyroxane derivatives and their use as hair growth promotors |
NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
EP1634876A3 (en) * | 2000-05-26 | 2007-03-14 | Nippon Shinyaku Co., Ltd. | Heterocyclic compounds for the treatment of hyperlipidemia agents |
UA75083C2 (ru) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Производные гликопептидфосфонатов |
FR2828487B1 (fr) | 2001-08-09 | 2005-05-27 | Genfit S A | Nouveaux composes derives d'acides gras, preparation et utilisations |
JP2005514437A (ja) | 2001-12-21 | 2005-05-19 | スリーエム イノベイティブ プロパティズ カンパニー | イオン対複合体を含む医薬用エアロゾル製剤 |
GB2383355A (en) | 2001-12-22 | 2003-06-25 | Schlumberger Holdings | An aqueous viscoelastic fluid containing hydrophobically modified polymer and viscoelastic surfactant |
MXPA04007382A (es) | 2002-01-31 | 2004-10-11 | Tfl Ledertechnik Gmbh | Composiciones y su uso para impartir repelencia al agua a cuero o pieles, textiles y otros materiales fibrosos. |
AU2003251518B2 (en) | 2002-06-13 | 2009-07-02 | New York University | Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
FR2845991B1 (fr) | 2002-10-16 | 2005-02-04 | Pf Medicament | Derives d'alpha-phenyl acetanilides et leur application en therapeutique humaine |
US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
US20060247458A1 (en) | 2003-02-28 | 2006-11-02 | Shogo Yamamoto | Process for the production of optically active compounds having substituents at the 2-position |
DE10326303A1 (de) | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
US20090215895A1 (en) * | 2004-01-30 | 2009-08-27 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
JP4563114B2 (ja) | 2004-08-30 | 2010-10-13 | 出光興産株式会社 | 潤滑剤用添加剤 |
WO2006109491A1 (ja) | 2005-03-31 | 2006-10-19 | Yamaguchi University | 波力エネルギー変換装置 |
US20090203778A1 (en) | 2005-05-04 | 2009-08-13 | Morten Bryhn | Fatty acid analogues, i.e. including dha derivatives for uses as a medicament |
CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
US20070167529A1 (en) | 2006-01-17 | 2007-07-19 | Walton Rebecca A | Antimicrobial compositions for treating fabrics and surfaces |
ES2391305T3 (es) | 2006-04-12 | 2012-11-23 | Unilever N.V. | Composición oral que comprende un ácido graso poliinsaturado y ácido salicílico para obtener un efecto antiinflamatorio en la piel |
EP1849449A1 (en) | 2006-04-26 | 2007-10-31 | 3M Innovative Properties Company | Filler containing composition and process for production and use thereof |
US7763607B2 (en) | 2006-04-27 | 2010-07-27 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators |
CN101489544A (zh) | 2006-05-09 | 2009-07-22 | 海玛奎斯特医药公司 | 治疗血液病的方法 |
CN101535238A (zh) * | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
WO2008053340A1 (en) | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
CN101225064A (zh) | 2007-01-19 | 2008-07-23 | 上海汇瑞生物科技有限公司 | 一种制备β-硫杂-α-烷基脂肪酸的新方法 |
DE102007017179A1 (de) * | 2007-04-12 | 2008-10-23 | Clariant International Ltd. | Verfahren zur Herstellung von Alkylpolyglykolcarbonsäuren und Polyglykoldicarbonsäuren mittels Direktoxidation |
US8604004B2 (en) * | 2007-10-04 | 2013-12-10 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
EP2217558A1 (en) | 2007-10-31 | 2010-08-18 | Pronova Biopharma Norge AS | New dha derivatives and their use as medicaments |
US8741966B2 (en) | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
FR2933006B1 (fr) | 2008-06-27 | 2010-08-20 | Inst Francais Du Petrole | Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante |
ES2656793T3 (es) | 2008-07-08 | 2018-02-28 | Catabasis Pharmaceuticals, Inc. | Salicilatos acetilados de ácidos grasos y sus usos |
EP2147910A1 (en) | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
TWI558395B (zh) * | 2009-05-08 | 2016-11-21 | 普諾華生物製藥諾治股份有限公司 | 新穎的脂質化合物 |
BR112012004677A2 (pt) | 2009-09-01 | 2020-11-03 | Catabasis Pharmaceuticals, Inc. | conjugados de ácido graxo niacina e seus usos |
TW201138832A (en) | 2010-01-20 | 2011-11-16 | Pronova Biopharma Norge As | Salicylate fatty acid derivatives |
EA028535B1 (ru) | 2010-11-05 | 2017-11-30 | Пронова Биофарма Норге Ас | Способы лечения с применением липидных соединений |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013016531A2 (en) | 2011-07-26 | 2013-01-31 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer |
-
2010
- 2010-05-07 TW TW099114670A patent/TWI558395B/zh active
- 2010-05-07 NZ NZ596386A patent/NZ596386A/en unknown
- 2010-05-07 PT PT10772077T patent/PT2427415T/pt unknown
- 2010-05-07 EP EP10772077.3A patent/EP2427415B1/en active Active
- 2010-05-07 MX MX2011011614A patent/MX2011011614A/es active IP Right Grant
- 2010-05-07 ES ES10772077T patent/ES2726765T3/es active Active
- 2010-05-07 TR TR2019/05768T patent/TR201905768T4/tr unknown
- 2010-05-07 EA EA201171371A patent/EA021177B1/ru not_active IP Right Cessation
- 2010-05-07 NZ NZ618734A patent/NZ618734A/en unknown
- 2010-05-07 PL PL10772077T patent/PL2427415T3/pl unknown
- 2010-05-07 MY MYPI2011005299A patent/MY165292A/en unknown
- 2010-05-07 AU AU2010244136A patent/AU2010244136B2/en active Active
- 2010-05-07 BR BRPI1015120A patent/BRPI1015120B8/pt active IP Right Grant
- 2010-05-07 DK DK10772077.3T patent/DK2427415T3/da active
- 2010-05-07 US US13/319,101 patent/US8735436B2/en active Active
- 2010-05-07 MA MA34421A patent/MA33341B1/fr unknown
- 2010-05-07 CN CN201080030436.5A patent/CN102459142B/zh active Active
- 2010-05-07 WO PCT/IB2010/001251 patent/WO2010128401A1/en active Application Filing
- 2010-05-07 AR ARP100101568A patent/AR078507A1/es active IP Right Grant
- 2010-05-07 MX MX2014000881A patent/MX366137B/es unknown
- 2010-05-07 SG SG2011079613A patent/SG175401A1/en unknown
- 2010-05-07 KR KR1020117028820A patent/KR101783817B1/ko active IP Right Grant
- 2010-05-07 CA CA2760877A patent/CA2760877C/en active Active
- 2010-05-07 JP JP2012509111A patent/JP5843755B2/ja active Active
- 2010-07-05 UA UAA201113181A patent/UA109528C2/ru unknown
-
2011
- 2011-11-04 CL CL2011002745A patent/CL2011002745A1/es unknown
- 2011-11-07 ZA ZA2011/08163A patent/ZA201108163B/en unknown
- 2011-11-07 IL IL216171A patent/IL216171A/en active IP Right Grant
- 2011-12-07 CO CO11168717A patent/CO6430454A2/es active IP Right Grant
-
2013
- 2013-05-30 ZA ZA2013/03962A patent/ZA201303962B/en unknown
-
2014
- 2014-04-11 US US14/250,980 patent/US20140221439A1/en not_active Abandoned
-
2015
- 2015-04-24 PH PH12015500930A patent/PH12015500930A1/en unknown
- 2015-07-31 JP JP2015151385A patent/JP2016026146A/ja active Pending
-
2017
- 2017-10-03 AR ARP170102752A patent/AR109789A2/es unknown
-
2019
- 2019-04-17 HR HRP20190732TT patent/HRP20190732T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201171371A1 (ru) | Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями | |
MY153620A (en) | Novel sulphur containing lipids for use as food supplementor as medicament | |
RU2017121277A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
NZ596228A (en) | Compositions and methods for the treatment of inflammation | |
ATE540932T1 (de) | Hydantoin-derivate als antibakterielle wirkstoffe | |
DOP2012000225A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
NZ594395A (en) | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia | |
MX2013004588A (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
BR112013023847A2 (pt) | composições farmacêuticas compreendendo ésteres de sorbitano | |
NZ601001A (en) | Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue | |
MX2009009838A (es) | Esteres de acidos grasos de glucocorticoides como agentes antiinflamatorios y anti-cancer. | |
MX2013006877A (es) | Composiciones farmaceuticas para inhibidores selectivos del factor xa para administracion oral. | |
NZ599268A (en) | Pharmaceutical compositions of rhein or diacerein made by wet granulation process | |
JP2016501248A5 (ru) | ||
WO2010079413A3 (en) | Dipeptidyl peptidase iv inhibitors | |
PH12021550744A1 (en) | Aromatic compounds and pharmaceutical uses thereof | |
MX342824B (es) | Nuevos compuestos de triazol iii. | |
WO2010004579A3 (en) | Orally active curcuminoid compounds | |
MY185985A (en) | Cleansing composition | |
MX2013002462A (es) | Compuestos heterociclicos como inhibidores de dgat1. | |
EP2428202A3 (en) | Orally disintegrating compositions | |
NZ597861A (en) | 2-amino-2-phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same | |
UA86561C2 (ru) | ЭТИЛОВЫЙ ЭСТЕР 9-МЕТИЛ-3-ОКСО-2,3-ДИГИДРОТИЕНО[3,2-e][1,2,4]ТРИАЗОЛО[4,3-c]ПИРИМИДИН-8-КАРБОНОВОЙ КИСЛОТИ, КОТОРЫЙ ПРОЯВЛЯЕТ АНАЛЬГЕТИЧЕСКУЮ И ПРОТИВОВОСПАЛИТЕЛЬНУЮ АКТИВНОСТЬ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |